Donanemab trials for Alzheimer's disease

All Donanemab trials · All Alzheimer's disease trials

Phase breakdown

Recruiting trials studying Donanemab for Alzheimer's disease

• A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease
  NCT06566170 · Phase: Not specified · Ages: 60 Years and older · Sex: All (male and female) · 1 location
• A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
  NCT07602582 · Phase: Phase 3 · Ages: 55 Years and older · Sex: All (male and female) · 59 locations
• A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
  NCT07589595 · Phase: Phase 2 · Ages: 55 Years to 85 Years · Sex: All (male and female) · 72 locations
• A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease
  NCT06996730 · Phase: Phase 2, Phase 3 · Ages: 25 Years to 65 Years · Sex: All (male and female) · 1 location
• Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease
  NCT07571161 · Phase: Phase 3 · Ages: 55 Years to 80 Years · Sex: All (male and female) · 30 locations

Common questions

How many trials study Donanemab for Alzheimer's disease?

5 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.